Communiqués Invivyd, Inc.

Actions

IVVD

US00534A1025

Temps réel estimé Cboe BZX Autres places de cotation 20:52:29 26/06/2024			Varia. 5j.	Varia. 1 janv.
1,21 ^USD	0,00%		-6,87%	-69,04%

14/06	Invivyd annonce l'activité antivirale de VYD222 (pemivibart) contre les variantes KP.1.1 FLiRT et KP.3 du SARS-CoV-2	CI
31/05	Invivyd en alignement général avec la FDA sur la voie de l'autorisation d'utilisation d'urgence pour les anticorps monoclonaux Covid	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants	14/06	GL
Invivyd to Participate at the Jefferies Global Healthcare Conference	03/06	GL
INVIVYD ANNOUNCES GENERAL ALIGNMENT WITH U.S. FDA ON A REPEATABLE, EXPEDIENT EMERGENCY USE AUTHORIZATION PATHWAY FOR THE PREVENTION AND TREATMENT OF SYMPTOMATIC COVID-19, BASED ON COMPACT CLINICAL PROGRAMS	03/06	AQ
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies	31/05	GL
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer	31/05	GL
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)	29/05	GL
Invivyd Elects Two New Independent Members to its Board of Directors	22/05	GL
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05	GL
Invivyd : Q1 2024 Invivyd Earnings Conference Call	10/05	PU
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05	GL
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback	07/05	GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights	02/05	GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights	02/05	AQ
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position	30/04	GL
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO	15/04	AQ
INVIVYD ANNOUNCES CEO TRANSITION	15/04	AQ
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™	15/04	GL
Invivyd Announces CEO Transition	12/04	GL
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million	04/04	GL
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights	28/03	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Invivyd, Inc.

Actions

IVVD

US00534A1025

Communiqués

Filtres